AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21276583 — intervention group
Group type: COMPARATOR
Intervention: Neutral faces in production task
Number of subjects: 0
Study 21276583 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry faces in temporal generalization task
Number of subjects: 0
Study 21276583 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry faces in reproduction task
Number of subjects: 0
Study 18704672 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard story format
Number of subjects: 45
Study 18704672 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive story format
Number of subjects: 45
Study 18704672 — intervention group
Group type: COMPARATOR
Intervention: Control story condition
Number of subjects: 45
Study 16399189 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblator
Number of subjects: 134
Study 16399189 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 134
Study 16399189 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic Scalpel
Number of subjects: 134
Study 15230027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed information pamphlet
Number of subjects: 0
Study 15230027 — intervention group
Group type: COMPARATOR
Intervention: No mailed pamphlet (usual care)
Number of subjects: 0
Study 11724129 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of gel containing 2% lidocaine
Number of subjects: 147
Study 11724129 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of gel without lidocaine
Number of subjects: 147
Study 11724129 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of gel containing 2% lidocaine
Number of subjects: 147
Study 11724129 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of gel without lidocaine
Number of subjects: 147
Study 9446253 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF, 2.5 micrograms/kg/day s.c. for the first 3 days followed by GM-CSF, 2.5 micrograms/kg/day s.c. for the last 3 days
Number of subjects: 0
Study 9446253 — intervention group
Group type: COMPARATOR
Intervention: G-CSF, 2.5 micrograms/kg/day s.c. from the 8th day to the 13th day of cycle
Number of subjects: 0
Study 8323356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment for one week
Number of subjects: 41
Study 8323356 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 41
Study 2877043 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 23
Study 2877043 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23
Study 2877043 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 30110706 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.067 mg/kg/day r‐hGH for 12 months
Number of subjects: 90
Study 30110706 — intervention group
Group type: COMPARATOR
Intervention: 6 months of no treatment followed by 0.067 mg/kg/day r‐hGH for 6 months
Number of subjects: 90
Study 27997608 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Electrical Stimulation (PES) treatment (1.33Hz/16Hz burst mode), for 14 days
Number of subjects: 12
Study 26098483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenugreek seeds (10 g/d)
Number of subjects: 88
Study 26098483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g/d of wheat starch)
Number of subjects: 88
Study 22960615 — intervention group
Group type: EXPERIMENTAL
Intervention: New silicone hydrogel SCLs
Number of subjects: 417
Study 20182424 — intervention group
Group type: EXPERIMENTAL
Intervention: AM103 (50-1000 mg single dose)
Number of subjects: 0
Study 20182424 — intervention group
Group type: EXPERIMENTAL
Intervention: AM103 (50-1000 mg once daily for 11 days)
Number of subjects: 0
Study 20182424 — intervention group
Group type: EXPERIMENTAL
Intervention: AM103 (all doses)
Number of subjects: 0
Study 18442848 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural categories
Number of subjects: 0
Study 18442848 — intervention group
Group type: EXPERIMENTAL
Intervention: Artifactual categories
Number of subjects: 0
Study 18442848 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of perceptual vs. functional features
Number of subjects: 0
Study 15721724 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 70
Study 15721724 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 70
Study 14682086 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 37
Study 14682086 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 11018854 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day (T100)
Number of subjects: 99
Study 11018854 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg/day (T200)
Number of subjects: 99
Study 11018854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 9277651 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 45 mg vaginal gel (group A, n = 14)
Number of subjects: 40
Study 9277651 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 90 mg vaginal gel (group B, n = 13)
Number of subjects: 40
Study 9277651 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone 180 mg vaginal gel (group C, n = 13)
Number of subjects: 40
Study 9277651 — intervention group
Group type: COMPARATOR
Intervention: Estradiol (E2) administered for 28 days prior to progesterone treatment
Number of subjects: 40
Study 9277651 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy performed on day 20 or 24
Number of subjects: 40
Study 8510910 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented group (severing the medial check ligaments and intermuscular membranes)
Number of subjects: 101
Study 8510910 — intervention group
Group type: COMPARATOR
Intervention: Nonaugmented group (no surgery on medial check ligaments or intermuscular membranes)
Number of subjects: 101
Study 3016439 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (125 micrograms/kg, then 1 microgram/kg/min)
Number of subjects: 0
Study 3016439 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 29235664 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion PUVA
Number of subjects: 60
Study 29235664 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 60
Study 27506771 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 35,000 IU/week vitamin D3
Number of subjects: 160
Study 27506771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 24773191 — intervention group
Group type: EXPERIMENTAL
Intervention: RTR+ (a modified version of Reducing the Risk curriculum)
Number of subjects: 734
Study 24773191 — intervention group
Group type: EXPERIMENTAL
Intervention: RTR (Reducing the Risk curriculum)
Number of subjects: 734
Study 24773191 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 734
Study 24773191 — intervention group
Group type: EXPERIMENTAL
Intervention: RTR+
Number of subjects: 734
Study 23813984 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory 1 Hz rTMS over the right triangular part of the posterior inferior frontal gyrus
Number of subjects: 24
Study 23813984 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 20606518 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (3 months of vigorous aerobic exercise at 80% to 85% of maximal heart rate, supervised 3 times per week)
Number of subjects: 39
Study 20606518 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic (no aerobic exercise)
Number of subjects: 39
Study 18307608 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruit and match/randomize procedure
Number of subjects: 0
Study 18307608 — intervention group
Group type: COMPARATOR
Intervention: Match/randomize and recruitment procedure
Number of subjects: 0
Study 15926164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 45
Study 15926164 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 45
Study 12674587 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive and hypolipidemic drugs
Number of subjects: 0
Study 12674587 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering blood pressure below 140/90 mm Hg and LDL‐cholesterol below 3 mmol/l (or even < 2.6 mmol/l)
Number of subjects: 0
Study 12674587 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor assessment including gender, age, family history, smoking, diabetes, blood pressure, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride
Number of subjects: 0
Study 10955849 — intervention group
Group type: EXPERIMENTAL
Intervention: Most patent nasal cavity
Number of subjects: 0
Study 10955849 — intervention group
Group type: EXPERIMENTAL
Intervention: Least patent nasal cavity
Number of subjects: 0
Study 10955849 — intervention group
Group type: COMPARATOR
Intervention: Total clearance of radiolabeled saline
Number of subjects: 0
Study 8826868 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (arm A)
Number of subjects: 141
Study 8826868 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU + IFN (arm B)
Number of subjects: 141
Study 29332235 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily diaries
Number of subjects: 324
Study 29332235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly diaries
Number of subjects: 324
Study 29332235 — intervention group
Group type: COMPARATOR
Intervention: Control (no diaries)
Number of subjects: 324
Study 29332235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary participants (combined)
Number of subjects: 324
Study 29332235 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly automated feedback
Number of subjects: 324
Study 27493132 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 835
Study 27493132 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 835
Study 27493132 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 835
Study 27493132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 835
Study 25515244 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% squalamine ointment
Number of subjects: 20
Study 25515244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23761652 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals
Number of subjects: 52
Study 23761652 — intervention group
Group type: COMPARATOR
Intervention: Mixture of NaFeEDTA and FeSO4
Number of subjects: 52
Study 23761652 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals with extra ascorbic acid (AA)
Number of subjects: 52
Study 23761652 — intervention group
Group type: COMPARATOR
Intervention: FeSO4-fortified meals with standard AA concentration
Number of subjects: 52
Study 23761652 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals with phytase without extra AA
Number of subjects: 52
Study 23761652 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO4-fortified meals with phytase with extra AA
Number of subjects: 52
Study 23761652 — intervention group
Group type: COMPARATOR
Intervention: FeSO4-fortified meals without phytase
Number of subjects: 52
Study 21416311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine IV (0.5 μg/kg bolus over 10 min and 0.5 μg/kg/h infusion) with local anesthesia (lidocaine 2% with epinephrine)
Number of subjects: 49
Study 21416311 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (15 ml of 0.25% bupivacaine + 100 μg fentanyl)
Number of subjects: 49
Study 18575012 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS) in group B (2004)
Number of subjects: 123
Study 18575012 — intervention group
Group type: COMPARATOR
Intervention: Non-computer-assisted surgery in group A (2003)
Number of subjects: 123
Study 18575012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 123
Study 16012523 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant radiotherapy (60 Gy over 30 fractions)
Number of subjects: 119
Study 16012523 — intervention group
Group type: COMPARATOR
Intervention: Concurrent combination chemotherapy and radiotherapy (66 Gy in 33 fractions)
Number of subjects: 119
Study 16012523 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery followed by adjuvant radiotherapy
Number of subjects: 119
Study 16012523 — intervention group
Group type: COMPARATOR
Intervention: Concurrent combination chemotherapy and radiotherapy
Number of subjects: 119
Study 11810100 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume of exercise in mid and late pregnancy
Number of subjects: 75
Study 11810100 — intervention group
Group type: COMPARATOR
Intervention: Reduced exercise volume after the 20th week
Number of subjects: 75
Study 10365740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Dalteparin)
Number of subjects: 314
Study 10365740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 10365740 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Dalteparin and Placebo)
Number of subjects: 314
Study 7486898 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola Classic (240 ml) with ketoconazole (200 mg)
Number of subjects: 9
Study 7486898 — intervention group
Group type: COMPARATOR
Intervention: Water with ketoconazole (200 mg) (control)
Number of subjects: 9
Study 7486898 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with ketoconazole (200 mg) after omeprazole (60 mg)
Number of subjects: 9
Study 2044949 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic elaboration
Number of subjects: 714
Study 2044949 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive imagery
Number of subjects: 714
Study 2044949 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 714
Study 6262930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazoline (1 gram) administered 30 minutes before operation
Number of subjects: 59
Study 6262930 — intervention group
Group type: COMPARATOR
Intervention: Untreated cases (control group)
Number of subjects: 59
Study 30976797 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 80
Study 30976797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28891900 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction of zygomatic arch fractures (Group A)
Number of subjects: 32
Study 28891900 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction with C‐arm fluoroscan and balloon support (Group B)
Number of subjects: 32
Study 25432641 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-controlled radiofrequency (TCRF)
Number of subjects: 84
Study 25432641 — intervention group
Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BRF)
Number of subjects: 84
Study 25077100 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood pressure measurement in physician's office (Group A)
Number of subjects: 275
Study 25077100 — intervention group
Group type: COMPARATOR
Intervention: Automated blood pressure measurement in pharmacy (Group B)
Number of subjects: 275
Study 25077100 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood pressure measurement in both settings
Number of subjects: 275
Study 21509053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (NEDV)
Number of subjects: 0
Study 21509053 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated vasodilation (EDV)
Number of subjects: 0
Study 21509053 — intervention group
Group type: COMPARATOR
Intervention: NEDV and EDV in hypertensive patients
Number of subjects: 0
Study 19644897 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver ring splints (SRS)
Number of subjects: 50
Study 19644897 — intervention group
Group type: COMPARATOR
Intervention: Commercial prefabricated thermoplastic splints (PTS)
Number of subjects: 50
Study 19644897 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 50
Study 19644897 — intervention group
Group type: COMPARATOR
Intervention: PTS
Number of subjects: 50
Study 17103167 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radio-chemotherapy (NARCT)
Number of subjects: 70
Study 17103167 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 70
Study 17103167 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in the standardized uptake value (SUV) of more than 80%
Number of subjects: 70
Study 17103167 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive disease according to PET
Number of subjects: 70
Study 17103167 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete tumour resection
Number of subjects: 70
Study 15136318 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate and dorzolamide hydrochloride (timolol-dorzolamide)
Number of subjects: 50
Study 15136318 — intervention group
Group type: COMPARATOR
Intervention: Timolol alone
Number of subjects: 50
Study 15136318 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide alone
Number of subjects: 50
Study 15136318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 11352855 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low activity genotype of mEH
Number of subjects: 974
Study 11352855 — intervention group
Group type: EXPERIMENTAL
Intervention: mEH genotype and cumulative smoking interaction
Number of subjects: 974
Study 9158268 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (30 micrograms/day for three weeks)
Number of subjects: 57
Study 9158268 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (0.9 mg/kg for three weeks)
Number of subjects: 57
Study 9158268 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine followed by Desmopressin
Number of subjects: 57
Study 9158268 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin followed by Imipramine
Number of subjects: 57
Study 7689205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (2.0‐2.9 mg/kg)
Number of subjects: 6
Study 7689205 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (2.5‐3.3 mg/kg)
Number of subjects: 6
Study 7689205 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (3.3‐3.7 mg/kg)
Number of subjects: 6
Study 3310763 — intervention group
Group type: EXPERIMENTAL
Intervention: Normomagnesemic group (4 out of 9)
Number of subjects: 22
Study 3310763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermagnesemic group (8 patients)
Number of subjects: 22
Study 3310763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomagnesemic group (5 patients)
Number of subjects: 22
Study 3310763 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cardiac arrest victims (13 out of 22)
Number of subjects: 22
Study 3310763 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 matched controls)
Number of subjects: 22
Study 29552010 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (ω‐3) supplementation
Number of subjects: 22
Study 29552010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study 28221819 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Injection Sclerotherapy (EIS)
Number of subjects: 124
Study 28221819 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Variceal Ligation (EVL)
Number of subjects: 124
Study 26790797 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐flexion posterior stabilized mobile bearing design (HF‐PS)
Number of subjects: 47
Study 26790797 — intervention group
Group type: COMPARATOR
Intervention: Standard cruciate retaining fixed bearing design (CR)
Number of subjects: 47
Study 23489103 — intervention group
Group type: EXPERIMENTAL
Intervention: Halita™ mouthrinse
Number of subjects: 36
Study 23489103 — intervention group
Group type: EXPERIMENTAL
Intervention: meridol(®) mouthrinse
Number of subjects: 36
Study 23489103 — intervention group
Group type: EXPERIMENTAL
Intervention: Halita™ with zinc lactate
Number of subjects: 36
Study 23489103 — intervention group
Group type: EXPERIMENTAL
Intervention: meridol(®) with zinc lactate
Number of subjects: 36
Study 23489103 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 36
Study 23489103 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 36
Study 21251856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored web-based intervention providing individualized audit data and peer comparisons
Number of subjects: 46
Study 21251856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored web-based intervention
Number of subjects: 46
Study 18475293 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX) 175 mg m(‐2)
Number of subjects: 849
Study 18475293 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX) 210 mg m(‐2)
Number of subjects: 849
Study 18475293 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg m(‐2)
Number of subjects: 849
Study 18475293 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX)
Number of subjects: 849
Study 18475293 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 849
Study 16606640 — intervention group
Group type: EXPERIMENTAL
Intervention: Central assessment by three blinded embryologists using 2D images
Number of subjects: 688
Study 16606640 — intervention group
Group type: COMPARATOR
Intervention: Local assessment versus consolidated central assessment (different methods)
Number of subjects: 688
Study 16606640 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidated central assessment by three embryologists
Number of subjects: 688
Study 12355999 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide‐like diuretic, slow‐release indapamid
Number of subjects: 0
Study 12355999 — intervention group
Group type: COMPARATOR
Intervention: Converting enzyme inhibitor, enalapril 20 mg
Number of subjects: 0
Study 10692717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg tablets
Number of subjects: 560
Study 10692717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 8941836 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use carbamide peroxide tooth-whitening procedure
Number of subjects: 52
Study 8941836 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 52